Losartan Potassium Tablets, 50 Mg Tablet
Product Images NDC 59746-334

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 50 Mg (NDC 59746-334). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg

This is a medication description for Losartan Potassium USP, available in the form of coated tablets with 100 mg strength. The tablets should be kept out of the reach of children and stored at a temperature range of 15-30°C. The medication is produced by Jublant Caista Pharmaceuticas in Maryland, USA. No additional information is available.*

FDA Label Image

25mg

This is a medication for Losartan Potassium USP in 25 mg tablets with usual dosage instructions provided in the accompanying package. The medication should be stored at 25°C and kept out of the reach of children. It is manufactured by Jubilant Cadista Pharmaceutical Inc. in the USA and comes in a bottle containing 30 tablets.*

FDA Label Image

50mg

Losartan Potassium is a medication contained in a bottle with a National Drug Code of 59746-334-30. Each coted ablet contains 50mg of Losatan Potassium USP. The usual dosage of medication is prescribed in the paonet labeled "Losartan Potassium". The Keoptismidmedcaionsotol Tablets are USP quality and come in a bottle that should be kept out of reach of children. The tablets should be protected from light and stored at room temperature (up to 25°C) but are allowed to be stored at a temperature of up to 150°C (66°F). The manufacturer is Cadista, and the package contains 30 tablets. Pharmacies that dispense the medication should accompany it with a patent information leaflet.*

FDA Label Image

Figure 1 (Figure1)

FDA Label Image

Figure 2 (Figure2)

The text is describing a study that compared the effectiveness of Atenolol and Losartan Potassium in reducing the risk of stroke. The study found that Losartan had a 25% risk reduction compared to Atenolol, with a p-value of 0.001. The graph shows the percentage of patients over the study months.*

FDA Label Image

Figure 3 (Figure3)

This appears to be a table showing the primary endpoint events within demographic subgroups for a study comparing the effectiveness of the medications Losartan and Atenolol in treating stroke. The subgroups are broken down by age, gender, race, diabetes status, and history of cardiovascular disease. Each subgroup's number of events, rate, and hazard ratio are listed for both medications. There are symbols proportional to sample size.*

FDA Label Image

Figure 4.jpg (Figure4)

The text appears to be a table containing data related to patients and treatment with Losartan Potassium and Placebo. It shows a Risk Reduction of 16.1% with 80 patients experiencing an event. The data is presented in a grid format with columns for the treatment and a timeline of 12, 24, and 48 weeks. Other details are not available from the given text.*

FDA Label Image

Losartan Potassium, Usp (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.